Table 2.
Head-to-head comparisons of treatment pattern and tumor response between the propensity score matched treatment groups
| Comparison | Platinum/Pemetrexed vs. Platinum/Docetaxel | Platinum/Pemetrexed vs. Platinum/Paclitaxel | Platinum/Pemetrexed vs. Platinum/Gemcitabine | Platinum/Pemetrexed vs. Platinum/Vinorelbine | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Matched pairs | 95 | RR | P value* | 118 | RR | P value* | 199 | RR | P value* | 72 | RR | P value* | ||||||||||||||||||||
| Measured outcomes | N | Mean/% | STDEV | N | Mean/% | STDEV | N | Mean/% | STDEV | N | Mean/% | STDEV | N | Mean/% | STDEV | N | Mean/% | STDEV | N | Mean/% | STDEV | N | Mean/% | STDEV | ||||||||
| Treatment pattern | ||||||||||||||||||||||||||||||||
| Completed treatment cycles | 95 | 3.4 | 1.7 | 95 | 2.9 | 1.7 | 0.028 | 118 | 3.6 | 1.7 | 118 | 2.9 | 1.6 | 0.006 | 199 | 3.6 | 1.7 | 199 | 2.7 | 1.5 | <0.001 | 72 | 3.3 | 1.7 | 72 | 2.5 | 1.3 | 0.003 | ||||
| Length of hospital stay per cycle (days) | 95 | 10.1 | 6.7 | 95 | 11.5 | 8.2 | 0.191 | 118 | 10.4 | 6.1 | 118 | 13.5 | 11.7 | 0.011 | 199 | 10.9 | 6.0 | 199 | 15.0 | 7.0 | <0.001 | 72 | 13.1 | 7.2 | 72 | 16.9 | 8.5 | 0.001 | ||||
| Tumor response based on RECIST (%) | ||||||||||||||||||||||||||||||||
| PR | 13 | 13.7% | 13 | 13.7% | 1.000 | 1.000 | 22 | 18.6% | 6 | 5.1% | 3.647 | 0.002 | 36 | 18.1% | 18 | 9.1% | 1.989 | 0.007 | 16 | 22.2% | 9 | 12.5% | 1.776 | 0.108 | ||||||||
| SD | 44 | 46.3% | 29 | 30.5% | 1.518 | 0.025 | 45 | 38.1% | 32 | 27.1% | 1.406 | 0.074 | 72 | 36.2% | 52 | 26.1% | 1.387 | 0.043 | 28 | 38.9% | 18 | 25.0% | 1.556 | 0.077 | ||||||||
| PD | 9 | 9.5% | 13 | 13.7% | 0.693 | 0.371 | 11 | 9.3% | 21 | 17.8% | 0.522 | 0.059 | 24 | 12.1% | 23 | 11.6% | 1.043 | 0.879 | 7 | 9.7% | 12 | 16.7% | 0.581 | 0.197 | ||||||||
| Unknown | 29 | 30.5% | 40 | 42.1% | 0.724 | 0.101 | 40 | 33.9% | 59 | 50.0% | 0.678 | 0.020 | 67 | 33.7% | 106 | 53.3% | 0.632 | <0.001 | 21 | 29.2% | 33 | 45.8% | 0.638 | 0.029 | ||||||||
| Other tumor response outcomes (%) | ||||||||||||||||||||||||||||||||
| Early treatment discontinuation | 45 | 47.4% | 62 | 65.3% | 0.726 | 0.007 | 52 | 44.1% | 71 | 60.2% | 0.732 | 0.022 | 91 | 45.7% | 135 | 67.8% | 0.674 | <0.001 | 38 | 52.8% | 55 | 76.4% | 0.691 | 0.007 | ||||||||
| Tumor control | 57 | 60.0% | 42 | 44.2% | 1.357 | 0.029 | 67 | 56.8% | 38 | 32.2% | 1.764 | <0.001 | 108 | 54.3% | 70 | 35.2% | 1.543 | <0.001 | 44 | 61.1% | 20 | 27.5% | 2.222 | 0.005 | ||||||||
| Treatment failure | 38 | 40.0% | 53 | 55.8% | 0.717 | 0.029 | 51 | 43.2% | 80 | 67.8% | 0.637 | <0.001 | 91 | 45.7% | 129 | 64.8% | 0.705 | <0.001 | 28 | 38.9% | 45 | 72.5% | 0.537 | 0.005 | ||||||||
STDEV, standard deviation; RR, rate ratio; RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, stable disease; PD, progressive disease. *: P values less than 0.05 were in bold to indicate significant differences.